Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Pfizer divested 7.3% remaining stake in Haleon, or approximately 662 million shares, to institutional investors and Haleon itself for £3.85 per ordinary share (around £2.5 billion). Pfizer sold ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3 ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

AstraZeneca, a global, science-led biopharmaceutical company, and Alteogen Inc., a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics ...

Alteogen's landscape ... a U.S. subsidiary of AstraZeneca. The total contract value is $1.35 billion (about 1.964 trillion won), and the contract fee is $45 million (about 65.2 billion won).

Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, ...

AstraZeneca and its wholly owned subsidiary MedImmune will leverage the Hybrozyme platform technology. ALT-B4 therapy ...